NCT04364464View on ClinicalTrials.gov

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 19, 2010

Primary Completion Date

March 17, 2011

Study Completion Date

September 20, 2011

Conditions
Clinical Pharmacology
Interventions
DRUG

Riociguat (Adempas, BAY 63-2521)

0.5 mg riociguat as an immediate-release (IR) tablet

Trial Locations (1)

24105

Kiel

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04364464 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight | Biotech Hunter | Biotech Hunter